Search Videos and More
Showing 1 - 11 of 11 results
News
Study Reveals Factor That Determines ‘Fate’ of Cancer Cells When Tumor Suppressor Gene Function is Restored
Many cancers develop from cells that have a malfunctioning tumor suppressor gene, p53, which normally helps control unchecked cell growth and prevent cancer.
News
Cancer Screenings Rebounded in Late 2020 After COVID-related Decline, but Racial and Economic Disparities Remain for Some Tests
The numbers of cancer screening tests rebounded sharply in the last quarter of 2020, following a dramatic decline in the first months of the COVID-19 pandemic, at one large hospital system in the Northeastern United States. These findings were released in a study published in Cancer Cell. The research also found an increase in racial and socioeconomic disparities among users of some screening tests during the pandemic.
News
Dana-Farber at ASCO
The Annual Meeting of the American Society of Clinical Oncology (ASCO) will take place virtually June 4-8th.
News
Immunotherapy Drug Delays Recurrence in Kidney Cancer Patients
Treatment with an immunotherapy drug following kidney cancer surgery, prolonged disease-free survival rates in patients at high risk for recurrence, according to an interim report of a phase 3 clinical trial of adjuvant immunotherapy in this patient population.
News
Dana-Farber Researchers Present Key Studies at ASCO Annual Meeting
Dana-Farber Cancer Institute researchers are presenting dozens of research studies at the 2021 Annual Meeting of the American Society of Clinical Oncology (ASCO). The studies will be presented during the virtual program on June 4-8, 2021. ASCO is the world’s largest clinical cancer research meeting, attracting more than 30,000 oncology professionals from around the world.
News
Immunotherapy Combination Shows Benefit for Patients with Advanced Melanoma, Phase 3 Trial Shows
A combination of two drugs that target different proteins on immune system T cells kept advanced melanoma in check significantly longer than one of the drugs alone in a phase 3 clinical trial involving 714 patients. Dana-Farber Cancer Institute investigators co-led the study. Findings will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, being held virtually June 4-8, 2021, and are included in the ASCO press program.
News
mRNA Takes Center Stage in COVID-19 Vaccine and Cancer Research
Having come to fame as the basis of the Moderna and Pfizer/BioNTech vaccines for COVID-19, messenger RNA — or mRNA — is in many ways the molecule of the moment.
News
Dana-Farber Cancer Institute Faculty Recognized as 2021 ASCO Leaders in Cancer Care
The American Society of Clinical Oncology (ASCO) recognized two Dana-Farber Cancer Institute researchers as winners of ASCO's Special Awards, the Society’s highest honors. The recipients of these awards have worked to transform cancer care around the world.
News
Expert Panel Issues Recommendations for Addressing Cancer Inequities
New recommendations co-developed by Dana-Farber Cancer Institute call for a significant expansion of the National Cancer Institute (NCI) and NCI-designated Comprehensive Cancer Centers to understand the causes of inequities in cancer care and a commitment to building sustained community partnerships to reduce them.
News
Eric P. Winer Elected ASCO President for Term Starting in June 2022
The American Society of Clinical Oncology (ASCO) has elected Eric P. Winer, MD, to serve as its President for the term beginning in June 2022. He will take office as President-Elect during the ASCO Annual Meeting in June 2021. Winer is the chief clinical development officer, senior vice president for medical affairs, chief of the Division of Breast Oncology, and the Thompson Chair in Breast Cancer Research at Dana-Farber Cancer Institute. He is also a professor of medicine at Harvard Medical School.
Video
Dana-Farber Research Looks at Blood Test to Detect Cancer
Dana-Farber’s Deborah Schrag, MD, MPH, is leading the Pathfinder Study, a study that looks at a simple blood test and evaluates it to see if it could detect multiple cancer types at the earliest and most treatable stages.